Liquidia Corp (LQDA) Surged Following the Successful Acceptance of Its YUTREPIA Drug

In its first-quarter 2026 capitalist letter, Laughing Water Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is simply a biopharmaceutical institution focuses connected improvement and commercialization of assorted products for uncommon cardiopulmonary diseases. On April 23, 2026, Liquidia Corporation (NASDAQ:LQDA) closed astatine $37.46 per share. One-month instrumentality of Liquidia Corporation (NASDAQ:LQDA) was 5.77%, and its shares gained 162.39% implicit the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a marketplace capitalization of $3.26 billion.

Laughing Water Capital stated the pursuing regarding Liquidia Corporation (NASDAQ:LQDA) successful its Q1 2026 capitalist letter:

"Liquidia Corporation (NASDAQ:LQDA) - Liquidia is our shaper of a cause called YUTREPIA that combats Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Interstitial Lung Disease (PH-ILD). The income motorboat of this cause continues to transcend each expectations, and the banal has appreciated nicely. However, I judge shares would beryllium overmuch higher if not for an on-going patent conflict with United Therapeutics (UTHR). Legal arguments successful the past circular concluded past summer, but the justice has not yet ruled. My enactment astir the opinions of ineligible experts and past rulings successful akin cases by this justice suggest a favorable result is connected the way. The hold is of people frustrating, but I deliberation the apt mentation is that the justice is taking the clip to constitute an sentiment that would beryllium slug impervious connected appeal. Logically, if helium were going to regularisation against Liquidia helium would bash truthful quickly, due to the fact that each time that helium has not ruled is different time that much patients are enactment connected YUTREPIA, and historically judges person not wanted to propulsion medicine from radical whose lives are improved by it.

Importantly, this proceedings is lone tied to the usage of YUTREPIA to dainty PH-ILD. In different words, adjacent if the ruling is unfavorable Liquidia should beryllium capable to proceed to instrumentality stock successful the PAH market. This should supply downside extortion for the stock. If the ruling is favorable and the motorboat of YUTREPIA continues unimpeded, adjacent a worldly dilatory down successful the complaint of adoption since inception could pb to a gross tally complaint northbound of $1.2B by the extremity of the year. If Liquidia were to commercialized astatine the aforesaid aggregate of income arsenic United Therapeutics, shares would beryllium worthy much than treble wherever they are today. Additionally, the large pharmaceutical companies are facing an estimated $300B successful patent cliffs implicit the adjacent fewer years. These aforesaid companies person an estimated $1T successful adust pulverization to marque acquisitions successful bid to capable successful the looming patent hole. Liquidia appears to beryllium a premier campaigner for a takeout by ample pharma."